ArticleCureus2024
Profiles of Peripheral Neuropathy and Risk Factors in People With Treatment-Naive Type 2 Diabetes Mellitus and Prediabetes.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting risk factors and strategies for prevention of peripheral neuropathy: focus on B-vitamin deficiencies and metabolic diseases.Neurological research and practice · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic peripheral neuropathy (DPN) is the most common complication of both type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus (T1DM) occurring in a majority of the affected people. DPN is the key initiating factor for the development of diabetic foot ulceration and the most common cause of non-traumatic lower-limb amputations. Whether chronic hyperglycaemia per se or altered levels of intermediate conventional risk factors in these people are responsible for the increased risk of DPN, is a matter of debate. There is little data about the profile of DPN in people with treatment-naive diabetes and prediabetes in the Asian population.
objectivesThis study aimed to determine the frequency of early DPN among people with newly detected treatment-naive diabetes and prediabetes attending a tertiary care public hospital. The study further aimed to determine the risk factors associated with DPN and to investigate whether such risk factors in these people might help to explain their increased risk of peripheral neuropathy.
methodsA total of 65 consecutive people with treatment-naive T2DM with an equal number of people with prediabetes attending a tertiary care centre, diagnosed as per standard criteria, were enrolled in a non-randomised prospective study. The presence of peripheral neuropathy was assessed by the Michigan Neuropathy Screening Instrument (MNSI). Risk factor analysis for peripheral neuropathy in both groups was carried out. Statistical significance was considered with p-values of < 0.05.
resultA total of 13 (20%) people with newly diagnosed treatment-naive T2DM and eight (12.3%) with prediabetes had DPN (MNSI score ≥ 2.5). Age (p < 0.001), high plasma glucose/glycated haemoglobin (HbA1c) (p < 0.001), BMI (p < 0.001), total cholesterol (p <0.001), albuminuria and hypertension (p < 0.001) were found to be strongly associated with early peripheral neuropathy.
conclusionDPN is a frequent complication among newly diagnosed treatment-naive people with T2DM and to a lesser extent among people with prediabetes. Various anthropometric, clinical, biochemical and metabolic factors in people with hyperglycaemia could account for the increased frequency of DPN in these people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.